President Donald Trump has selected Heidi Overton, a physician and deputy director of the White House Domestic Policy Council, to serve as the next commissioner of the Food and Drug Administration — a choice that comes as the agency navigates serious internal upheaval and a leadership vacuum that has persisted for months.
The Selection
Overton brings a substantial medical background to the role. She earned her medical degree from the University of New Mexico and completed general surgery training at Johns Hopkins, where she also pursued research training at the Bloomberg School of Public Health. Before joining the White House, she worked at the America First Policy Institute.
She was one of three candidates under consideration. The others were Jeffrey Vacirca, an oncologist, and Stephen Ferrara, a Pentagon health official. Her proximity to the administration’s health policy agenda appears to have been a decisive factor — she was present at a White House event last week when Trump signed an executive order directing a review of the childhood vaccine schedule, including a directive to split the combined measles, mumps, and rubella vaccine into three separate shots. Health experts have noted that developing three standalone vaccines could take drug developers several years to accomplish.
A Troubled Agency in Need of Stability
The FDA has been operating without a confirmed leader since May, when Marty Makary stepped down just 13 months into his tenure after clashing with White House officials and health advisers. Kyle Diamantas has been serving as acting chief since then.
The personnel situation at the agency has been severe. Over the past year, the FDA has lost more than 3,000 staff members, including division heads. In April, Vinay Prasad, who led the biologics division, departed amid controversy over proposed revisions to vaccine trial standards and the rejection of certain rare-disease drug applications.
Since Diamantas assumed acting leadership, the agency has reversed course or reopened regulatory pathways for rare-disease therapies from Regenxbio, uniQure, and Replimune. The FDA has also taken steps to accelerate drug research by connecting pharmaceutical sponsors with qualified research institutions — signals that the agency is attempting to restore momentum and rebuild credibility with the medical and pharmaceutical communities.
What It Means Going Forward
Overton’s nomination, if confirmed by the Senate, would place a trusted White House insider at the helm of an agency that oversees the safety and approval of virtually every drug, medical device, and food product that reaches American families. The stakes are significant: a functional, efficient FDA directly affects patients waiting on life-saving treatments, small medical innovators seeking regulatory clarity, and taxpayers who fund the agency’s operations.
The Biden-era FDA drew criticism for sluggish approval timelines and regulatory overreach. Trump’s FDA has faced a different set of challenges — rapid staff turnover, leadership instability, and policy disputes that spilled into public view. Whether Overton can consolidate authority and restore the agency’s operational footing will be among the most consequential health-policy questions of the administration’s second term.
The White House, the FDA, and Overton herself had not responded to requests for comment as of the time this report was filed. A formal nomination has not yet been announced.
Category: Republic | Tags: White House, Health Policy, Heidi Overton, FDA